Business update

AI SummaryClose X

Trellus Health plc reported progress in its clinical trials and pharmaceutical verticals, securing a 12-month contract with ICON plc for Takeda-sponsored trials and a similar contract with PSI Inc. for Sanofi-sponsored trials, alongside ongoing support for an AstraZeneca Phase 2 trial. The company also advanced its collaboration with Johnson & Johnson and renewed its agreement with Pfizer, while expecting revenue of approximately $545,000 for the year ended 2025 and reducing its monthly cash burn to around $400,000. A £5 million convertible facility with Alumni Capital LLC was approved, with the first tranches totaling £737,500 expected to extend the cash runway into late Q1 2026, and discussions for further funding are ongoing.

Disclaimer*

UK 100

Latest directors dealings